JP7460369B2 - Ｇｐｒ６のテトラヒドロピリドピラジンモジュレーター - Google Patents

Ｇｐｒ６のテトラヒドロピリドピラジンモジュレーター Download PDF

Info

Publication number
JP7460369B2
JP7460369B2 JP2019563277A JP2019563277A JP7460369B2 JP 7460369 B2 JP7460369 B2 JP 7460369B2 JP 2019563277 A JP2019563277 A JP 2019563277A JP 2019563277 A JP2019563277 A JP 2019563277A JP 7460369 B2 JP7460369 B2 JP 7460369B2
Authority
JP
Japan
Prior art keywords
disease
composition according
dose
group
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019563277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523287A5 (https=
JP2020523287A (ja
Inventor
ダブリュー． ブラウン，ジェイソン
ヒッチコック，ステファン
ホプキンス，マリア
キクチ，ショウタ
モネスチェイン，ホルガ―
リチャード，ホーリー
シュライヒャー，クリスティン
サン，フイカイ
マックリン，トッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2020523287A publication Critical patent/JP2020523287A/ja
Publication of JP2020523287A5 publication Critical patent/JP2020523287A5/ja
Priority to JP2022160819A priority Critical patent/JP7497400B2/ja
Application granted granted Critical
Publication of JP7460369B2 publication Critical patent/JP7460369B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019563277A 2017-06-15 2018-06-15 Ｇｐｒ６のテトラヒドロピリドピラジンモジュレーター Active JP7460369B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022160819A JP7497400B2 (ja) 2017-06-15 2022-10-05 Ｇｐｒ６のテトラヒドロピリドピラジンモジュレーター

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762520430P 2017-06-15 2017-06-15
US62/520,430 2017-06-15
US201762591247P 2017-11-28 2017-11-28
US62/591,247 2017-11-28
US201862649856P 2018-03-29 2018-03-29
US62/649,856 2018-03-29
US201862672261P 2018-05-16 2018-05-16
US62/672,261 2018-05-16
PCT/US2018/037687 WO2018232202A1 (en) 2017-06-15 2018-06-15 Tetrahydropyridopyrazine modulators of gpr6

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022160819A Division JP7497400B2 (ja) 2017-06-15 2022-10-05 Ｇｐｒ６のテトラヒドロピリドピラジンモジュレーター

Publications (3)

Publication Number Publication Date
JP2020523287A JP2020523287A (ja) 2020-08-06
JP2020523287A5 JP2020523287A5 (https=) 2021-07-26
JP7460369B2 true JP7460369B2 (ja) 2024-04-02

Family

ID=64656005

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019563277A Active JP7460369B2 (ja) 2017-06-15 2018-06-15 Ｇｐｒ６のテトラヒドロピリドピラジンモジュレーター
JP2022160819A Active JP7497400B2 (ja) 2017-06-15 2022-10-05 Ｇｐｒ６のテトラヒドロピリドピラジンモジュレーター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022160819A Active JP7497400B2 (ja) 2017-06-15 2022-10-05 Ｇｐｒ６のテトラヒドロピリドピラジンモジュレーター

Country Status (25)

Country Link
US (1) US10406157B2 (https=)
EP (1) EP3638673B9 (https=)
JP (2) JP7460369B2 (https=)
KR (1) KR102802861B1 (https=)
CN (1) CN110730781B (https=)
AU (1) AU2018285677B2 (https=)
CA (1) CA3067032A1 (https=)
CO (1) CO2019015086A2 (https=)
DK (1) DK3638673T3 (https=)
ES (1) ES2988680T3 (https=)
FI (1) FI3638673T3 (https=)
HR (1) HRP20241231T1 (https=)
HU (1) HUE068346T2 (https=)
IL (1) IL271332B2 (https=)
JO (1) JOP20180057A1 (https=)
LT (1) LT3638673T (https=)
MX (1) MX2019014940A (https=)
PH (1) PH12019502792A1 (https=)
PL (1) PL3638673T3 (https=)
PT (1) PT3638673T (https=)
RS (1) RS66018B1 (https=)
SG (1) SG11201912149WA (https=)
SI (1) SI3638673T1 (https=)
TW (1) TWI775874B (https=)
WO (1) WO2018232202A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026067262A1 (zh) * 2024-09-26 2026-04-02 四川科伦药物研究院有限公司 并环化合物、包含其的药物组合物及其用途和方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502027A (ja) 2013-12-20 2017-01-19 武田薬品工業株式会社 Ｇｐｒ６のテトラヒドロピリドピラジンモジュレーター

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US7229557B2 (en) 2004-02-04 2007-06-12 Konec, Inc. Method to separate stereoisomers
US20120101106A1 (en) 2009-07-09 2012-04-26 Mercer Swati P Tetrahydronapthyridine Orexin Receptor Antagonists
JP6526034B2 (ja) 2014-02-14 2019-06-05 武田薬品工業株式会社 Ｇｐｒ６のピリドピラジンモジュレーター
KR20160122215A (ko) * 2014-02-14 2016-10-21 다케다 야쿠힌 고교 가부시키가이샤 Gpr6의 피라진 조절제

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502027A (ja) 2013-12-20 2017-01-19 武田薬品工業株式会社 Ｇｐｒ６のテトラヒドロピリドピラジンモジュレーター

Also Published As

Publication number Publication date
EP3638673A4 (en) 2021-03-24
PT3638673T (pt) 2024-10-07
IL271332A (en) 2020-01-30
RS66018B1 (sr) 2024-11-29
EP3638673A1 (en) 2020-04-22
MX2019014940A (es) 2020-02-19
JOP20180057A1 (ar) 2019-01-30
KR102802861B1 (ko) 2025-04-30
JP2022188199A (ja) 2022-12-20
FI3638673T3 (fi) 2024-09-13
LT3638673T (lt) 2024-09-10
HUE068346T2 (hu) 2024-12-28
CA3067032A1 (en) 2018-12-20
KR20200014796A (ko) 2020-02-11
IL271332B (en) 2022-10-01
ES2988680T3 (es) 2024-11-21
US20180360831A1 (en) 2018-12-20
SI3638673T1 (sl) 2025-01-31
TWI775874B (zh) 2022-09-01
WO2018232202A1 (en) 2018-12-20
AU2018285677A1 (en) 2019-12-19
BR112019026430A2 (pt) 2020-07-14
EP3638673B9 (en) 2024-11-20
EP3638673B1 (en) 2024-07-17
CO2019015086A2 (es) 2020-04-13
AU2018285677B2 (en) 2022-07-14
TW201906844A (zh) 2019-02-16
JP7497400B2 (ja) 2024-06-10
SG11201912149WA (en) 2020-01-30
NZ759708A (en) 2024-04-26
HRP20241231T1 (hr) 2024-12-20
JP2020523287A (ja) 2020-08-06
CN110730781B (zh) 2023-05-05
PL3638673T3 (pl) 2024-11-18
IL271332B2 (en) 2023-02-01
RU2019144408A (ru) 2021-07-15
US10406157B2 (en) 2019-09-10
CN110730781A (zh) 2020-01-24
DK3638673T3 (da) 2024-09-16
PH12019502792A1 (en) 2020-09-14
RU2019144408A3 (https=) 2021-09-07

Similar Documents

Publication Publication Date Title
JP7447002B2 (ja) ＳＨＰ２のオクタヒドロシクロペンタ［ｃ］ピロールのアロステリック阻害剤
AU2004299456B2 (en) (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
CN107108671B (zh) 作为raf激酶抑制剂的化合物和组合物
JP2015518895A (ja) Ｅｇｆｒ活性を調節するための化合物および組成物
TW202000659A (zh) 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
TW200804353A (en) Pyrazine derivatives
US20250188037A1 (en) N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
JP7497400B2 (ja) Ｇｐｒ６のテトラヒドロピリドピラジンモジュレーター
CN116854644B (zh) 5-氨基-1-烷基-1h-1,2,3-三氮唑-4-甲酰胺类化合物及其制备和应用
RU2818783C2 (ru) Тетрагидропиридопиразиновые модуляторы gpr6
HK40022760A (en) Tetrahydropyridopyrazine modulators of gpr6
HK40022760B (en) Tetrahydropyridopyrazine modulators of gpr6
BR112019026430B1 (pt) Composto de tetrahidropiridopirazina ou seus sais aceitáveis, composição comprendendo o mesmo, combinação, e seu uso no tratamento de doença relacionada ao gpr6
TWI920639B (zh) Shp2之八氫環戊烷并[c]吡咯別構抑制劑
JP2009515943A (ja) アミノ酸誘導体
JP2008542198A (ja) β‐アミノ酸誘導体
NL1026828C2 (nl) Derivaten van azachinazoline.
CN120424018A (zh) 5-氨基-1-取代-1h-1,2,3-三氮唑-4-甲酰胺类化合物及其制备和应用
CN1989107A (zh) 吡啶衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220422

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221005

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221005

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221013

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221018

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221216

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240321

R150 Certificate of patent or registration of utility model

Ref document number: 7460369

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150